Related Experiment Video
Updated: May 19, 2026
09:57
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
Risk-based classification of leukemia by cytogenetic and multiplex molecular methods: results from a multicenter
Blood Cancer Journal
|August 2, 2012
Summary
This study validates a new multiplex molecular assay for detecting leukemia fusion transcripts, showing high accuracy and sensitivity. This method aids in leukemia diagnosis, prognosis, and monitoring, complementing traditional cytogenetics.
Area of Science:
- Hematology
- Molecular Diagnostics
- Oncology
Background:
- Accurate diagnosis and prognosis of leukemia rely on identifying cytogenetic abnormalities.
- Current methods may not capture all relevant molecular markers for comprehensive patient management.
Purpose of the Study:
- To perform the first multicenter validation of a multiplex molecular assay for 12 key leukemia fusion transcripts.
- To compare the performance of this assay against standard cytogenetic methods and reference molecular tests.
Main Methods:
- Multiplex reverse transcription-polymerase chain reaction (RT-PCR) followed by liquid bead array detection.
- Evaluation on 280 adult and pediatric acute or chronic leukemia samples with diverse clinical presentations.
- Comparison with cytogenetics and independent reference molecular tests.
Main Results:
- High overall agreement (>98.5%) across four clinical sites.
- Excellent concordance with cytogenetic methods and high qualitative agreement (98.7%) with reference molecular tests.
- Demonstrated method sensitivity of 1% for detecting low blast count or relapsed cases.
Conclusions:
- The multiplex RT-PCR assay is a rapid, flexible, and accurate method for leukemia molecular profiling.
- This assay complements cytogenetic methods, providing valuable data for diagnosis, prognosis, and molecular monitoring.
- Potential for enhanced clinical sensitivity by incorporating rare variants and additional transcripts.
